Demant A/S DEMANT
OMXCOP · Denmark · Health Technology
DKK 311.20+1.20 (+0.39%)
Market open· · DKK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · DKK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Investing.com -- European medtech has had another bruising year, with only Demant and Sonova outperforming the Stoxx 600 in 2026 as the sector’s once-premium valuation continues to de-rate.
Demant AS (WILLF) reports 15% revenue growth in H1 2026, driven by successful product launches and strategic acquisitions, while raising its full-year guidance.
As European markets navigate the complexities of geopolitical developments and economic adjustments, indices like the STOXX Europe 600 have shown modest gains amid investor anticipation of a U.S.-Iran agreement. In this environment, identifying stocks that may be trading below their estimated value becomes crucial for investors seeking opportunities in undervalued assets. A good stock in such conditions often exhibits strong fundamentals and resilience to external shocks, offering potential...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.